Skip to main content

Table 2 Hospital anxiety and depression scale scores and functional assessment of chronic illness therapy-fatigue scores

From: Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

Instrument/ ETN + MTX DMARD + MTX P Value*
 Time on therapy Mean Score (% Improvement from Baseline) (N)  
Anxiety Subscale    
 Baseline 8.27 (0%) (N = 196) 8.19 (0%) (N = 103)  
 Week 16 5.84 (29.1%) (N = 192) 6.69 (18.5%) (N = 100) 0.026
Depression Subscale    
 Baseline 7.62 (0%) (N = 196) 7.85 (0%) (N = 103)  
 Week 16 5.42 (28.7%) (N = 192) 6.56 (16.4%) (N = 100) 0.016
FACIT-Fatigue    
 Baseline 28.1 (0%) (N = 146) 30.1 (0%) (N = 76)  
 Week 16 36.2 (28.0%) (N = 143) 33.2 (10.4%) (N = 73) 0.001
  1. Scores at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheumatoid Arthritis Patients Treated With ETN + MTX versus DMARD + MTX (Last Observation Carried Forward Analysis).
  2. DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy- Fatigue; MTX: methotrexate.
  3. *ANCOVA, considering the factors ‘baseline score + therapy + country’.